

- Jun 11, 2022
NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma


- Apr 7, 2022
NCT05317416: Phase 3: Elranatamab Versus Lenalidomide in Patients With NDMM post ASCT - MagnetisMM-7


- Mar 1, 2022
NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)


- Mar 1, 2022
NCT05257083: Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT- NDMM CARTITUDE-6


- Mar 1, 2022
NCT05256446: AMG 701 Expanded Access Program


- Mar 1, 2022
NCT05259839: Phase 1: IV Infused ABBV-383 With Anti-Cancer Regimens for Relapsed/Refractory Myeloma


- Dec 23, 2021
NCT04398745: Phase 1: Belantamab Mafodotin With Normal and Varying Degree of Impaired Renal Function


- Dec 20, 2021
NCT05164250: Compassionate Use (CU) of REGN5458 for Relapsed or Refractory Multiple Myeloma (MM)


- Dec 16, 2021
NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902


- Dec 16, 2021
NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma


- Dec 12, 2021
The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of RRMM treated with IRd


- Dec 11, 2021
Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of RRMM


- Dec 3, 2021
NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - MajesTEC-3


- Aug 31, 2021
NCT05028348: Phase 3: EMN 29 - Selinexor, Pom, Dex (SPd) Vs Elotuzumab, Pom, Dex in RRMM Myeloma


- Aug 27, 2021
NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers


- Aug 20, 2021
NCT05014412: Phase 1/2: Elranatamab in MM That Has Come Back or Has not responded - MagnetisMM-9


- Aug 7, 2021
NCT04910568: Phase 1b - Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma


- Aug 6, 2021
NCT04975997: Phase 3: IberDd Versus DVd in Participants With Relapsed Refractory Myeloma - EXCALIBER


- Aug 6, 2021
NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants RRMM